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Abstract
Introduction: Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy.
Azacitidine has promising activity in patients with low proliferating AML. The aim of this dose-finding part of this trial was to
evaluate feasibility and safety of azacitidine combined with a cytarabine- and daunorubicin-based chemotherapy in older
patients with AML.
Trial Design: Prospective, randomised, open, phase II trial with parallel group design and fixed sample size.
Patients and Methods: Patients aged 61 years or older, with untreated acute myeloid leukemia with a leukocyte count of
,20,000/ml at the time of study entry and adequate organ function were eligible. Patients were randomised to receive
azacitidine either 37.5 (dose level 1) or 75 mg/sqm (dose level 2) for five days before each cycle of induction (7+3 cytarabine
plus daunorubicine) and consolidation (intermediate-dose cytarabine) therapy. Dose-limiting toxicity was the primary
endpoint.
Results: Six patients each were randomised into each dose level and evaluable for analysis. No dose-limiting toxicity
occurred in either dose level. Nine serious adverse events occurred in five patients (three in the 37.5 mg, two in the 75 mg
arm) with two fatal outcomes. Two patients at the 37.5 mg/sqm dose level and four patients at the 75 mg/sqm level
achieved a complete remission after induction therapy. Median overall survival was 266 days and median event-free survival
215 days after a median follow up of 616 days.
Conclusions: The combination of azacitidine 75 mg/sqm with standard induction therapy is feasible in older patients with
AML and was selected as an investigational arm in the randomised controlled part of this phase-II study, which is currently
halted due to an increased cardiac toxicity observed in the experimental arm.
Trial Registration: This trial is registered at clinical trials.gov (identifier: NCT00915252).
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Introduction
Despite intensive treatment, acute myeloid leukemia (AML) in
elderly patients still has a dismal outcome with the vast majority of
patients succumbing to their disease within 2 years after diagnosis
[1]. Intrinsic biological differences lead to a complete remission
rate of only about 50% compared to approximately 70% in elderly
patients [1,2]. Aberrant DNA methylation patterns can frequently
be detected in AML blasts [3], and gene mutations that alter DNA
methylation patterns were recently identified in AML, among
them mutations of the isocitrate dehydrogenase genes (IDH) 1 and
2 [4] and DNA methyltransferase 3A [5]. The hypomethylating
agents azacitidine and decitabine are able to reverse aberrant
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e52695promoter hypermethylation by inhibition of DNA methyltransfer-
ases [6]. Clinical activity with prolongation of survival compared
to conventional care was demonstrated for azacitidine in patients
with high-risk myelodysplastic syndrome (MDS) and low prolifer-
ating AML with up to 30% bone marrow blasts [7,8] and ongoing
trials currently evaluate the efficacy of azacitidine and decitabine
in AML with .30% bone marrow blasts. However, despite their
clinical activity, these compounds do not lead to long-term
remissions.
In vitro data suggest a synergistic effect of cytarabine and
azacitidine when azacitidine is administered before cytarabine
exposure [9]. This might in part be explained by the induction of
deoxycytidine kinase (dCK) by azacitidine. dCK phosphorylates
cytarabine to its active compound, ara-CTP [10].
While high-dose cytarabine has demonstrated strong clinical
activity [11], the failure of chemotherapy to cure a patient of AML
is often due to cellular cytarabine resistance [12]. Several potential
resistance mechanisms are discussed, among those an inactivity of
dCK. In a cytarabine-resistent, dCK-deficient leukemic cell line
originating from HL60, sensitivity towards cytarabine could be
restored upon induction of dCK by azacitidine [10].
Even though no inactivation of dCK could be demonstrated
in vivo in cytarabine resistant primary AML cells, a phase I-study
with 17 pediatric patients with relapsed acute lymphoblastic
leukemia (ALL) after high-dose cytarabine treatment yielded a
complete remission in two out of 9 evaluable patients after
treatment with azacitidine followed by another course of high-dose
cytarabine [13].
The aim of this pilot trial was to establish the preliminary safety
profile of azacitidine added to standard induction and consolida-
tion therapy in older patients with newly diagnosed AML, and to
determine the recommended dose for a subsequent controlled
phase II trial.
Patients and Methods
Study Design and Eligibility
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The dose finding trial reported herein was a
prospective, randomised, open-label phase II trial with parallel
group design and fixed sample size preceeding an open-label,
randomised, controlled, multicenter phase II trial of the study
alliance leukemia (SAL). Participating centers of the dose finding
part of this trial were the University Hospitals of Muenster,
Frankfurt am Main, Dresden and Essen, all located in Germany.
The trial was registered at www.clinicaltrials.gov (identifier:
NCT00915252, URL: http://clinicaltrials.gov/ct2/show/
NCT00915252). The study was approved by the Ethics Commit-
tee of the University of Muenster and conducted in accordance
with the Declaration of Helsinki. Written, informed consent was
obtained from all patients before study enrolment.
Patients with .60 years of age with untreated AML (excluding
acute promyelocytic leukemia) were eligible. Exclusion criteria
were: Known central nervous system manifestation of AML, heart
failure class 3 or 4 according to New York Heart Association,
unstable coronary artery disease, serious cardiac ventricular
arrhythmias requiring anti-arrhythmic therapy beyond beta
blockers or digoxin, inadequate renal (creatinin clearance
,30 ml/min) or hepatic function (serum total bilirubin $1.5
upper limit of normal (ULN), alanine aminotransferase (ALT) or
aspartate aminotransferase (AST) $2.56ULN not caused by
leukemic infiltration), known human immunodeficiency virus and/
or hepatitis C infection, evidence or history of severe non-leukemia
associated bleeding diathesis or coagulopathy, evidence or recent
history of CNS disease, including primary or metastatic brain
tumors, seizure disorders, uncontrolled active infection, concur-
rent malignancies other than AML with an estimated life
expectancy of less than two years, history of organ allograft,
hypersensitivity to cytarabine (not including drug fever or
exanthema), daunorubicin, azacitidine or mannitol and previous
therapy with azacitidine (i.e. for an antecedent myelodysplastic
syndrome). An exclusion criterion only for the dose finding part of
this trial was a leukocytosis .20,000/ml at study entry. For the
controlled part of the trial, those patients were eligible if the
leukocyte count could be decreased to ,20,000/ml with hydroxy-
urea.
Randomisation
Patients were randomised 1:1 between 37.5 (dose level 1) and
75 mg/sqm (dose level 2) of azacitidine without stratification. This
parallel randomised evaluation allowed us a rapid evaluation of
two different dose levels of azacitidine, and ensured six patients
being treated with the recommended dose for the controlled part
of the study. The random allocation sequence was generated using
SAS software (proc plan). Randomisation lists were generated
using block randomisation with a block size of 4. Randomisation
was performed centrally providing allocation concealment.
Patients were first screened for eligibility at clinical sites without
having access to randomisation lists. Eligible patients were
reported to a central randomisation unit by fax. Subsequently
the intended intervention of each patient was reported back to
clinical investigators.
Treatment Plan
The treatment scheme is depicted in Fig. 1. After randomisa-
tion, patients received the randomised dose level of azacitidine on
days 25t o21 as intravenous (iv) infusion over 30 minutes,
followed by ‘7+3’ induction chemotherapy consisting of cytarabine
100 mg/sqm continuous iv infusion on days 1–7 and daunorubi-
cin 45 mg/sqm iv on days 3–5. The rationale for reducing the
azacitidine application per cycle to five days, as opposed to seven
days per cycle for monotherapy, were as follows: First, the five-
days application allowed for an application on weekdays, since
application on weekends poses problems in selected study centers.
Second, a pretreatment .5 days would prolong the delay of
initiation of cytotoxic therapy in those patients with untreated
AML. The maximum dose of 5675 mg/sqm resulted from
concerns regarding an additional cytotoxicity of the combination
of standard induction and postremission therapy and higher doses
of azacitidine. Dose level 1 of azacitidine was selected as 50% of
dose level 2 based on recommended dose reductions to 50% in
case of prolonged hematotoxicity by the manufacturer (investiga-
tional brochure and subsequent prescribing information).
An early bone marrow evaluation was performed seven days
after the end of the first induction therapy. A sufficient blast
clearance in the early bone marrow evaluation was defined as
,5% remaining leukemic blasts according to the revised
recommendations of the International Working Group for AML
[14]. Only in case of $5% residual bone marrow blasts did
patients receive an identical second induction course starting with
azacitidine on day 17. Patients that achieved a complete remission
(CR) after induction therapy received two consolidation courses of
azacitidine at the randomised dose level on days 25t o21
subcutaneously, followed by intermediate-dose cytarabine (1 g/
sqm bidaily iv on days 1, 3 and 5). Stopping rules included an
increase of the leukocyte count to .50.000/ml during the first five
days of azacitidine treatment. Such a patient would immediately
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therapy. A patient was evaluable if either 1. at least one therapy
cycle with azacitidine plus induction therapy was completed or 2.
patient received at least one day of therapy and a DLT occurred.
Patients with premature termination of either azacitidine treat-
ment and/or induction therapy during their first induction course
were evaluable only if a DLT occurred in this patient, otherwise,
such a patient would be replaced by another patient in this dose
level. Patients received supportive care including standard
antibiotic and antifungal prophylaxis according to each institu-
tion’s guidelines.
Primary and Secondary Endpoints
The primary endpoint of this dose finding study was safety and
toxicity of both dose levels. The recommended dose for the
controlled part of the trial was defined as the highest dose level
with one or less out of six evaluable patients experiencing a DLT.
A separate dose level 0 with azacitidine 18 mg/sqm would have
been evaluated in additional six patients in case of .1 DLT in
each dose level. If .1 DLT would have been occurred also in this
dose level 0, no azacitidine would have been administered
preceeding the cytotoxic cycles in the controlled part of the trial.
Adverse events (AE’s) and severe AE’s (SAE’s) were graded
according to NCI common toxicity criteria (CTC) v3.0. CTCAE
Grade 4 leukocytopenia, neutropenia, and thrombocytopenia as
signs of active antileukemic treatment were assessed as an SAE
only if persisting .42 days after the last application of cytotoxic
chemotherapy in patients with blast clearance with (CR) or
without (CRi) complete hematological recovery and then defined a
DLT.
Assessment of treatment response was performed seven days
after the end of the first induction cycle as described above, after
hematological recovery following induction therapy, but not later
than 35 days after the start of the last induction cycle, and every
three months after achievement of complete remission until disease
progression. Patients were monitored with physical examination,
complete blood count and chemistry profile at least once weekly
during induction and consolidation, and then at least monthly for
the first two years after treatment start during follow-up. Response
to treatment was defined according to the revised recommenda-
tions of the International Working Group for AML [14].
Cytogenetic and Molecular Analysis
Cytogenetic analysis was performed by classical G-banding as
previously described [15]. Molecular analysis for mutational status
of Nucleophosmin (NPM), fms-like tyrosine kinase 3 (FLT3),
additional sex combs like 1 (ASXL1), DNA methyltransferase 3A
(DNMT3A), ten-eleven translocation 2 (TET2), isocitrate dehydro-
genase 1 (IDH1) and 2 (IDH2) was performed as published
[16,17,18,19,20,21,22]. Primers for TET2 were modified from
[23] and are listed in Table S1. Cytogenetic and molecular risk
classification was performed according to the ELN 2010 criteria
[24].
Statistical Analysis
Overall survival was measured from the first day of azacitidine
treatment until death of any course. Event-free survival was
measured from the first day of treatment until therapy failure,
relapse or death of any course. Patients without an event were
censored at last follow-up. Follow-up time was calculated using
reverse censoring. These outcome parameters were determined
only exploratory for the total cohort. Statistical analyses were
performed using IBM SPSS Statistics 20 for Windows (IBM
Corporation, Somers, NY, USA).
Results
Patient Characteristics
Between September 2009 and February 2010, 12 patients were
included in this pilot trial; four from two centers each, and three
and one from the remaining centers, respectively. Data bank
snapshot was taken on February 15th, 2012. The CONSORT
statement of these patients is shown in Fig. 2. The clinical
characteristics of these patients are depicted in Table 1. Median
age was 68 years. Six patients were male. Median ECOG
performance status was 1. According to ELN 2010 classification,
Figure 1. CONSORT statement. The patient flow through this dose finding pilot trial is shown.
doi:10.1371/journal.pone.0052695.g001
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and 12) had intermediate-I risk, and three each intermediate-II
(no. 3, 6 and 11) and high risk (no. 1, 5 and 10) (Table 1). Detected
class III mutations are listed in Table 1 and Table S2.
Safety and Toxicity
No DLT occurred in either dose level. Nine severe adverse
events occurred in five patients, two in the 75 mg/sqm dose level
(two patients) and seven in the 37.5 mg/sqm dose level (three
patients) (Table 2, labelled with ‘SAE: yes’). In two patients, the
SAEs had a fatal outcome. 19 AE’s in ten patients were grade 3 or
higher, seven in the 75 mg/sqm dose level and twelve of them in
the 37.5 mg/sqm dose level (Table 2). With the exception of a
neutropenic septicemia which occurred after the second consol-
idation course (patient 9), neutropenic fever in patient 3 and drug
fever to cytarabine in both consolidation courses and diarrhea in
one consolidation course of patient 4, all other SAEs and AEs
grade 3 or 4 occurred during induction therapy. 162 AE’s of all
grades occurred, among them 102 in the 75 mg/sqm dose level
and 62 in the 37.5 mg/sqm dose level (Table S3). The most
frequently occurring AE’s were: fever (11), peripheral edemas (8),
diarrhea (8), nausea (8), vomiting (8), and exanthema (6). Infections
(20 versus 7), AE’s of the cardiovascular (19 versus 7),
musculoskelettal (5 versus 0) and gastrointestinal system (27 versus
22) were more frequent in the 75 mg/sqm compared to the
37.5 mg/sqm dose level. Among the AE’s of the cardiovascular
system were peripheral edemas (5 versus 3), hypertension (2 versus
1), hypotension (2 versus 0), tachycardia (2 versus 1), chest pain (2
versus 0), bradycardia (1 versus 0), arrhythmia (1 versus 0), cardiac
failure (Taku Tsuko cardiomyopathy, 0 versus 1), and vasovagal
syncope (1 versus 0 of the 75 mg/sqm versus the 37.5 mg/sqm
dose level, respectively) (Table S3). With the exception of one
cardiac failure in the 37.5 mg/sqm arm (Table 2), all AE’s of the
Table 2. Listing of all severe adverse events and adverse events grade 3 or 4.
Pat No term SAE grade (CTCAE) outcome AZA dose level
1 bladder pain no 3 resolved 75
1 pneumonia yes 5 death 75
2 neutropenic fever no 3 resolved 37.5
2 allergic exanthema no 3 resolved 37.5
3 neutropenic fever no 3 resolved 75
4 drug fever no 3 resolved 75
4 diarrhea no 3 resolved 75
4 drug fever no 3 resolved 75
5 diarrhea no 3 resolved 37.5
5 neutropenic fever no 3 resolved 37.5
5 hyperbilirubinemia yes 3 ongoing 37.5
5 Daunorubicin extravasation yes 2 resolved 37.5
7 apoplectic stroke yes 5 death
a 37.5
7 Reduced general condition no 4 ongoing 37.5
7 aseptic lymphocytic meningoencephalitis yes 2 resolved 37.5
7 moist crackles yes 5 death
a 37.5
9 neutropenic septicemia yes 4 resolved 75
10 acute hemolysis yes 4 resolved 37.5
10 cardiac failure (Taku Tsuko cardiomyopathy) yes 4 improved 37.5
11 neutropenic fever no 3 resolved 37.5
12 neutropenic fever no 3 resolved 37.5
The highest CTCAE grade of each event is listed. Hematotoxicity was not listed as adverse event unless persisting .42 days with grade IV after start of the last
chemotherapy cycle without evidence of persisting leukemia.
Abbreviations: AZA, 5-azacitidine; CTCAE, common terminology criteria for adverse events; SAE, serious adverse event.
aIn patient 7, both SAEs were documented with a fatal outcome.
doi:10.1371/journal.pone.0052695.t002
Figure 2. Outline of induction and consolidation therapy.
Patients were randomised between 37.5 mg/sqm (dose level 1) and
75 mg/sqm (dose level 2) of azacitidine administered before each cycle
of chemotherapy. Patients received 1–2 cycles of induction chemo-
therapy (‘7+3’) and responding patients received 2 cycles of consoli-
dation therapy (intermediate-dose cytarabine).
doi:10.1371/journal.pone.0052695.g002
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regeneration after induction and after consolidation therapy. After
induction therapy, median time to regeneration for patients in
37.5 mg/sqm and the 75 mg/sqm dose level was 23 and 25 days
to a leukocyte count of .1,000/ml, 29 and 28 days to a neutrophil
count .500/ml and 22 and 30 days to a transfusion-independent
platelet count .20,000/ml, respectively (all comparisons not
significant). In nine consolidation courses applied to five patients
in CR, median time to regeneration was 22 days for leukocytes, 27
days for neutrophils and 22 days for platelets.
Drug Delivery
Seven patients received one and five patients received two
induction courses. No patient had to be replaced due to
Figure 3. Hematotoxicity of induction and consolidation therapy. The time from start of chemotherapy until regeneration of leukocytes
.1,000/ml, neutrophils .500/ml and plateletes .20,000/ml (transfusion independent) is shown. A: induction therapy, B: consolidation therapy.
doi:10.1371/journal.pone.0052695.g003
Figure 4. Outcome of the entire trial population. A: overall survival, B: event-free survival.
doi:10.1371/journal.pone.0052695.g004
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in the protocol. Reasons for applying only one induction course
were complete blast clearance seven days after the end of the first
induction cycle (four patients), early death due to pneumonia
during the first course (one patient), progressive disease (one
patient) and an SAE (one patient). Of all seven responding
patients, four received both consolidation cycles. Two patients
proceeded to allogeneic stem cell transplantation (one after
induction, one after first consolidation) in first complete remission.
Treatment Outcome
The treatment outcome is depicted in Table 1. In all patients,
azacitidine was applied at the randomly allocated dose before the
first cytotoxic induction treatment. One early death occurred
during induction therapy before bone marrow evaluation. Of the
remaining 11 patients, four showed an adequate blast clearance
one week after the end of the induction cycle. Seven patients (four
in dose level 75 mg/sqm, three in dose level 37.5 mg/sqm)
achieved a CR after one (four patients) or two (three patients)
induction courses whereas two additional patients succumbed to
early death. One of the responding patients terminated study
participation due to serious adverse events and achieved a CR
without further therapy. Two patients had refractory disease after
induction therapy, of whom one patient achieved a CR after
termination of study participation and salvage therapy. After a
median follow-up of 616 days from start of therapy, median
overall and event-free survival of the entire cohort was 266 days
and 215 days, respectively (Fig. 4).
Of note is the outcome of patient no. 10. The patient with a
complex karyotype AML received one induction course with
azacitidine 37.5 mg/sqm followed by ‘7+3’. One week after
commencement of the first induction cycle, the bone marrow
evaluation showed persisting infiltration with 77% blasts. Due to
massive hemolysis (most likely fluorochinolone-induced) and
subsequent cardiac failure, both regarded as a SAE, trial treatment
was stopped on day 31 of therapy. Despite no further treatment
after termination of study participation, the patient achieved a
complete remission on day 69 (38 days after end of trial), while
both SAE’s resolved. The patient remained in CR with good
health and in the absence of further therapy for almost a year
before relapse occurred.
Outcome by ELN risk group revealed 2 out of 2 patients
achieving a CR with good risk, 2/4 patients with intermediate-I
risk, 2/3 patients with intermediate-II risk and 1/3 patients with
high risk.
Discussion
We herein present data of a dose finding trial to evaluate safety,
toxicity and feasibility of the addition of azacitidine to standard
induction and consolidation therapy in older, medically fit patients
with newly diagnosed AML. While intensive chemotherapy leads
to a CR rate of 50% in this patient group, the probability of long-
term survival is less than 10%, demonstrating the need for
alternative and more efficacious treatment options. Azacitidine has
a proven efficacy in patients with high-risk MDS and low-
proliferating AML with 30% bone marrow blasts or less [8,25],
even though this treatment is still considered to be palliative.
Therefore, it seems desirable to assess the efficacy of the drug in
combination with standard chemotherapy. We decided to
administer azacitidine before the cytotoxic therapy on the basis
of existing preclinical data suggesting beneficial effects of
azacitidine priming [10]. So far, azacitidine in a dosage of
75 mg/sqm has been evaluated in combination with high-dose
cytarabine in pediatric patients with relapsed, cytarabine-refrac-
tory ALL [13].
Since a combination of azacitidine with a cytarabine and
anthracyclines has not been evaluated, we assessed two different
dose levels of azacitidine to determine the maximal tolerated dose.
The seven complete remissions seen in our pilot trial are in line
with observed remission rates with intensive chemotherapy in this
entity and age group, and the observed survival rates are
encouraging.
Recent reports found an association with response to therapy in
patients carrying DNMT3A, ASXL1 or TET2 mutations [26–28].
In our cohort, the frequency of those class III mutations was too
low to draw any conclusions about a possible association with
response.
Regarding toxicity, we observed three early deaths during
induction therapy attributable to pneumonia, hepatorenal syn-
drome and apoplectic stroke, respectively. While the latter two
toxicities are uncommon, the death rate of 25% after an intensive,
cytarabine- and anthracycline-containing induction therapy in this
patient population is in line with published results [29]. The
majority of severe adverse events and adverse events grade 3 or
higher occurred in the 37.5 mg/sqm dose level, suggesting that an
increased azacitidine dose does not lead to an increased toxicity in
the dose range tested.
In our pilot trial, both dose levels could be safely administered
prior to standard cytotoxic induction and consolidation therapy.
Therefore, the independent Data Monitoring Committee (DMC)
suggested 75 mg/sqm for 5 days as the recommended dose for the
randomised controlled phase II part of this trial (AML-AZA,
clinicaltrials.gov identifier: NCT00915252). Eligible patients in
this open-label, controlled part of the trial are randomised 1:1
between the experimental or the control arm. Patients in the
experimental arm receive azacitidine 5675 mg/sqm prior to each
induction and, if responding, consolidation therapy cycles as
described above, and responding patients in the experimental arm
additionally receive a maintenance therapy after consolidation
with azacitidine 75 mg/sqm over 5 days s.c. q28 days for up to
one year after initiation of therapy. Patients in the control arm
directly receive induction therapy, consisting of 7+3 induction, and
responding patients receive consolidation therapy as described
above. No placebo-controlled design was chosen because of ethical
considerations (treatment of patients with untreated AML with
placebo for 5 days before initiating induction therapy). Sample size
of this controlled phase II part was initially planned for 216
subjects (108 each arm), with event-free survival being the primary
endpoint. However, recruitment is currently halted due to an
increased rate of cardiac toxicity observed in the experimental arm
after recruitment of 213 patients. The DMC recently stated that
there is no concern regarding a further conduct of the randomised
phase II trial, and results of this controlled part will be published
separately. Taken together, our results of the pilot trial reported
herein demonstrate that it might be feasible to add azacitidine
75 mg/sqm for 5 days to standard induction chemotherapy. This
is in line with a recently published phase I trial combining
standard induction therapy with the hypomethylating agent
decitabine, which also showed feasibility and promising CR rates
[30]. However, six patients treated in each dose level might not be
sufficient to fully evaluate the safety profile of this combination,
which is obvious considering the observed cardiac toxicity in the
controlled part of the trial. The combination of novel treatment
strategies with proven chemotherapy regimens warrants further
study in older patients with AML.
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